FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results
18 févr. 2021 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2020 financial results on Monday, March 1 after the market close....
FibroGen to Report Second Quarter 2020 Financial Results
23 juil. 2020 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen will...
FibroGen to Present at Upcoming Investor Conferences
27 mai 2020 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
FibroGen to Present at Bank of America Securities 2020 Health Care Conference
08 mai 2020 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on May...
Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update
07 nov. 2019 16h00 HE
|
Capricor Therapeutics, Inc.
Provides Update on End of Phase Type-B Meeting with FDA Positive Data from the HOPE-2 Clinical Trial Presented at World Muscle Society To Host Conference Call and Webcast Today at 4:30 p.m....
FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019
04 nov. 2019 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that financial results for the third quarter 2019 will be released after market on Monday, November...
Capricor Therapeutics to Present Third Quarter 2019 Financial Results and Recent Corporate Update on November 7
01 nov. 2019 09h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)
21 oct. 2019 09h25 HE
|
Capricor Therapeutics, Inc.
Call Scheduled for Thursday, October 24th at 10:30am Eastern Time LOS ANGELES, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (Nasdaq: CAPR), a clinical-stage biotechnology company...
Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months
07 oct. 2019 06h30 HE
|
Capricor Therapeutics, Inc.
--Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies-- --Company to Host Conference Call Today at 5:30 AM PT / 8:30 AM ET-- ...
Capricor to Present Interim Results from the HOPE-2 Trial in a Late Breaking Session of the World Muscle Society and Company to Host Conference Call Monday, October 7 at 5:30 AM PT / 8:30 AM ET
02 oct. 2019 09h15 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...